Management of oral lichen planus with triamcinolone acetonide and injectable platelet-rich fibrin

ISRCTN ISRCTN11783938
DOI https://doi.org/10.1186/ISRCTN11783938
Secondary identifying numbers MS3030
Submission date
18/06/2021
Registration date
09/07/2021
Last edited
09/07/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Skin and Connective Tissue Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Oral lichen planus is an inflammatory condition that affects the mucous membranes inside the mouth. This study aims to compare injectable platelet-rich fibrin and triamcinolone acetonide injections for the treatment of oral lichen planus.

Who can participate?
Patients over 18 years old with bilateral oral lichen planus

What does the study involve?
Participants are randomised by coin toss to decide which side of their mouth is to be treated with injectable platelet-rich fibrin and which is to be treated with triamcinolone acetonide. After local anaesthesia, the treatment is injected in several sites in the mouth once a week for 4 weeks. During the treatment, participants are assessed at weeks 0, 1, 2, 3, 4 and then once a month for 3 months.

What are the possible benefits and risks of participating?
The results of the study may lead to an effective and efficient treatment for oral lichen planus with few or no side effects.

When is the study starting and how long is it expected to run for?
April 2019 to October 2021

Where is the study run from?
Damascus University (Syria)

Who is funding the study?
Damascus University (Syria)

Who is the main contact?
Dr Noor Abdualrahman Alhallak
nooralhallak93@gmail.com

Contact information

Dr Noor Alhallak
Scientific

Mazzeh
Damascus
0096311
Syria

Phone +963 (0)934459512
Email noor7.alhallak@damascusuniversity.edu.sy

Study information

Study designSplit-mouth randomized controlled trial
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)Other
Study typeTreatment
Participant information sheet ISRCTN11783938_PIS.pdf
Scientific titleManagement of oral lichen planus lesions using intralesional platelet-rich fibrin and triamcinolone acetonide injection
Study objectivesThe researchers are trying to test the efficacy of injectable platelet-rich fibrin and comparing it to triamcinolone acetonide injection in the treatment of oral lichen planus.
Ethics approval(s)Approved 26/08/2019, Damascus University Rector (Baramkeh, Damascus, Syria; +966 (0)55 506 3806; email: not available), ref: MS3030
Health condition(s) or problem(s) studiedBilateral oral lichen planus lesions
InterventionThis study is a split-mouth randomised clinical trial. Participants are randomised by coin toss to decide which side of their mouth is to be treated by injectable platelet-rich fibrin and which is to be treated by triamcinolone acetonide (40 mg/ml). After local anesthesia, the injection is placed in several sites directly into the subepithelial connective tissue just underlying the lesion adjacent to normal mucosa, once a week for 4 weeks. During the treatment, participants are assessed at weeks 0, 1, 2, 3, 4 and then once a month for 3 months.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Injectable platelet-rich fibrin, triamcinolone acetonide
Primary outcome measurePain measured using a Visual Analog Scale (VAS) once a week during treatment for 4 weeks
Secondary outcome measures1. Clinical presentation of oral lichen planus measured using the REU scoring system at 1, 2, 3 and 4 weeks
2. Treatment response: surface areas of erythema and ulceration measured with a sterile flexible periodontal scale probe at 1, 2, 3 and 4 weeks
3. Recurrence rate measured by clinical examination at the end of treatment (day 30)
4. Quality of life measured using OHIP- 14 before treatment and at the end of treatment (day 30)
Overall study start date23/04/2019
Completion date01/10/2021

Eligibility

Participant type(s)Patient
Age groupMixed
SexBoth
Target number of participants12
Total final enrolment12
Key inclusion criteriaPatients diagnosed with oral lichen planus lesions
Key exclusion criteria1. Patients with systemic disease
2. A history of topical therapy for oral lichen planus in the last 2 weeks or systemic treatment for oral lichen planus in the last 3 months
3. Pregnancy or lactation
4. Patients who had taken immunodepressant drugs the past 3 months
Date of first enrolment15/09/2019
Date of final enrolment01/07/2021

Locations

Countries of recruitment

  • Syria

Study participating centre

Damascus University
Department of Oral Medicine
Mazzah High Way
Damascus
0096311
Syria

Sponsor information

Damascus University
University/education

Damascus University Rector
Baramkeh
Damascus
0096311
Syria

Phone +963 (0)1133923192
Email info@damascusuniversity.edu.sy
Website http://damasuniv.edu.sy/
ROR logo "ROR" https://ror.org/03m098d13

Funders

Funder type

University/education

Damascus University

No information available

Results and Publications

Intention to publish date01/09/2022
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planAfter finishing the follow-up procedure and writing the article, the researchers are planning to publish (with all results, statistical analysis and some photos) in Damascus University's journal, and many other international journals.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Dr Noor Abdualrahman Alhallak (nooralhallak93@gmail.com).

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet 09/07/2021 No Yes
Protocol file 09/07/2021 No No

Additional files

ISRCTN11783938_PIS.pdf
Uploaded 09/07/2021
ISRCTN11783938_PROTOCOL.pdf
Uploaded 09/07/2021

Editorial Notes

08/07/2021: Uploaded protocol (not peer reviewed). The participant information sheet has been uploaded.
06/07/2021: Trial's existence confirmed by Damascus University.